Clinical Trial News and Research

RSS

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.

27 Sep 2018

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

27 Sep 2018

CytoSen receives favorable response from FDA to its pre-IND meeting package for CSTD002-NK

CytoSen Therapeutics, a private biopharmaceutical company accelerating innovation in Natural Killer cell therapy, today announced it has received a favorable response from the U.S. Food and Drug Administration to its pre-Investigational New Drug meeting package for the proposed Phase 2 trial of CytoSen's adoptive NK cell therapy, CSTD002-NK, for the reduction of relapse in high risk acute myeloid leukemia or myelodysplastic syndrome in patients undergoing haploidentical hematopoietic stem cell transplantation.

27 Sep 2018

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.

27 Sep 2018

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics.

27 Sep 2018

Novel therapy technique double rate of upper limb recovery in stroke patients

A novel therapy technique invented by researchers at The University of Texas at Dallas has been shown in a pilot study to double the rate of upper limb recovery in stroke patients, a leap forward in treating the nearly 800,000 Americans who suffer strokes each year.

27 Sep 2018

AVITA Medical announces results revealing safety, effectiveness of RECELL System for burn care

AVITA Medical , a global regenerative medicine company, today announced that the results from two U.S. pivotal clinical trials demonstrating the effectiveness and clinical benefits of the RECELL Autologous Cell Harvesting Device were presented at the 46th Annual Eastern Great Lakes Burn Conference in Ann Arbor, Michigan.

27 Sep 2018

Scientists discover most important target of MRSA bacterial toxin and ways to neutralize it

For patients diagnosed with a Staphylococcus aureus infection, often referred to as a staph or MRSA infection, every minute counts.

27 Sep 2018

Lower clinical trial enrollment associated with relapse risk in AYA leukemia patients

Adolescent and young adult patients with acute lymphoblastic leukemia were significantly more likely to relapse than pediatric ALL patients, and factors including lower clinical trial enrollment and shorter duration of therapy were associated with relapse.

27 Sep 2018

Auto-FMT found to be safe, effective way to replenish beneficial gut bacteria in cancer patients

Researchers at Memorial Sloan Kettering Cancer Center have shown that autologous fecal microbiota transplantation (auto-FMT) is a safe and effective way to help replenish beneficial gut bacteria in cancer patients who require intense antibiotics during allogenic hematopoietic stem cell transplantation.

27 Sep 2018

Rutgers study uncovers new mechanism linked to Alzheimer's and traumatic brain injury

Rutgers researchers have discovered a new mechanism that may contribute to Alzheimer's disease and traumatic brain injury. They now hope to launch a clinical trial to test the treatment in humans.

27 Sep 2018

New drug to treat Parkinson's disease psychosis do not pose greater risk of death

In the wake of media and public reports about increased mortality linked to a new drug for treating Parkinson's disease psychosis -- a symptom of the progressive nervous system disorder in which patients experience hallucinations and delusions -- researchers at University of California San Diego School of Medicine conducted a retrospective study of qualifying patients in the UC San Diego Health system, concluding that the new drug, pimavanserin, did not pose a statistically significant greater risk of death.

27 Sep 2018

RTI Surgical showcases innovative spine portfolio at NASS 2018

RTI Surgical, Inc., a global surgical implant company, will showcase research reinforcing the strength of its spine portfolio, notably the Fortilink IBF series featuring TETRAfuse 3D Technology, at the North American Spine Society's 33rd Annual Meeting in Los Angeles, September 26-29.

26 Sep 2018

Urine exRNA may be source of biomarkers for muscular dystrophy

Massachusetts General Hospital researchers have found that extracellular RNA in urine may be a source of biomarkers for the two most common forms of muscular dystrophy, noninvasively providing information about whether therapeutic drugs are having the desired effects on a molecular level.

26 Sep 2018

Brigatinib drug may offer first-line treatment option for ALK-positive NSCLC

Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced ALK-positive non-small cell lung cancer.

26 Sep 2018

New TB vaccine effective in half of the population in phase II trials

GlaxoSmithKline has come up with an experimental vaccine against tuberculosis (TB) that has shown effective prevention of the infection in half of the population it has been administered to. This could be a breakthrough in preventing the killer disease say researchers since most of the recent vaccines developed against the disease have failed to show efficacy.

26 Sep 2018

Prostatectomy plus radiotherapy associated with greater survival in prostate cancer patients

High-risk prostate cancer, that which has continued to grow but not yet metastasized, is commonly treated with combination therapies. Each method has pros and cons, but there is little clarity whether one might be more effective than the other.

25 Sep 2018

Novel drug alleviates memory deficits and neuropathology in Alzheimer's animal model

New research conducted at the Lady Davis Institute at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology in an animal model.

25 Sep 2018

Cerevance starts dosing in Phase I clinical trial of CVN424 for treatment of Parkinson's disease

Cerevance, a clinical-stage drug discovery and development company focused on brain diseases, today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson's disease.

25 Sep 2018

Physical activity may have beneficial effects for people with rare Alzheimer's disease

For individuals carrying a genetic mutation that causes Alzheimer's disease, engaging in at least 2.5 hours of physical activity per week may have beneficial effects on markers of Alzheimer's disease brain changes and may delay cognitive decline, according to a new study available online by Alzheimer's & Dementia: The Journal of the Alzheimer's Association as an article in press, corrected proof.

25 Sep 2018

Clinical Trial News and Research

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

CytoSen receives favorable response from FDA to its pre-IND meeting package for CSTD002-NK

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Novel therapy technique double rate of upper limb recovery in stroke patients

AVITA Medical announces results revealing safety, effectiveness of RECELL System for burn care

Scientists discover most important target of MRSA bacterial toxin and ways to neutralize it

Lower clinical trial enrollment associated with relapse risk in AYA leukemia patients

Auto-FMT found to be safe, effective way to replenish beneficial gut bacteria in cancer patients

Rutgers study uncovers new mechanism linked to Alzheimer's and traumatic brain injury

New drug to treat Parkinson's disease psychosis do not pose greater risk of death

RTI Surgical showcases innovative spine portfolio at NASS 2018

Urine exRNA may be source of biomarkers for muscular dystrophy

Brigatinib drug may offer first-line treatment option for ALK-positive NSCLC

New TB vaccine effective in half of the population in phase II trials

Prostatectomy plus radiotherapy associated with greater survival in prostate cancer patients

Novel drug alleviates memory deficits and neuropathology in Alzheimer's animal model

Cerevance starts dosing in Phase I clinical trial of CVN424 for treatment of Parkinson's disease

Physical activity may have beneficial effects for people with rare Alzheimer's disease

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer